Beijing Tong Ren Tang Chinese Medicine Company (3613) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
31 Oct, 2025Executive summary
Announcement discloses that unaudited financial information for the nine months ended 30 September 2025 has been published by the controlling shareholder, Tong Ren Tang Technologies, on the Hong Kong Stock Exchange.
The parent company, Beijing Tong Ren Tang Ltd., will release its own unaudited results for the same period on the Shanghai Stock Exchange by 31 October 2025.
Significant events and developments
The announcement is made in compliance with Hong Kong regulatory requirements and references the publication of financial results by the controlling shareholder.
Shareholders and potential investors are advised to exercise caution when dealing in the company's securities.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Beijing Tong Ren Tang Chinese Medicine Company
- Revenue and profit fell, but cash and equity rose; global expansion and innovation prioritized.3613
Q4 202520 Mar 2026 - Revenue and profit fell over 17% year-over-year, but liquidity and R&D investment stayed strong.3613Q2 20242 Dec 2025
- Revenue and profit rose, driven by expansion, innovation, and strong cash position.3613Q2 20252 Dec 2025
- Controlling shareholder released unaudited nine-month 2024 results; caution advised.3613Q3 20242 Dec 2025
- Q1 2025 unaudited results released by the controlling shareholder; caution advised.3613Q1 20252 Dec 2025
- Revenue up 5.7% but net profit down 10.4% as Overseas sales fell and costs rose.3613Q4 20245 Jun 2025